FDA’s Woodcock Prioritizes Trial Networks As Drug Development Solution

Culture change, not congressional action is needed advance this step toward faster drug development, FDA’s drug leader tells Energy & Commerce Committee.

Center for Drug Evaluation and Research Director Janet Woodcock put clinical trial networks on the top of her list of what could be done to speed the development of new drugs at a May 6 congressional meeting on how to modernize and accelerate biomedical innovation – and it shouldn’t require legislation to spur the change, she noted.

“If you step back and look at the whole ecosystem I think there are some major barriers that academics and...